Fosun Pharma’s annual revenue reaches 41.7 billion yuan: domestic revenue down 4% year-on-year; Chen Zhanyu steps down as CFO

Fosun Pharma, Lei Jianping, April 6

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Stock code: 600196, short name: Fosun Pharma) recently released its financial report as of December 31, 2025. The report shows that Fosun Pharma’s revenue in 2025 was 41.66B yuan, an increase of 1.45% compared to 41.07B yuan in the same period last year.

Fosun Pharma’s total R&D investment in 2025 reached 5.91B yuan, with 72.77% of the R&D expenditure related to innovative drugs.

Fosun Pharma’s net profit in 2025 was 3.37B yuan, up 21.69% from 2.77 billion yuan in the same period last year; net profit after non-recurring gains and losses was 2.34 billion yuan, an increase of 1.12% compared to 2.31B yuan last year.

In Q4 2025, Fosun Pharma’s revenue was 12.27B yuan, with a net profit of 847 million yuan, and net profit after non-recurring gains and losses was 767 million yuan.

During the reporting period, the net cash flow from operating activities was 5.21B yuan, a year-on-year increase of 16.45%. Meanwhile, Fosun Pharma continued to promote the exit and integration of non-strategic, non-core assets, optimizing asset structure, accelerating cash inflows, and nearly 3 billion yuan was recovered within 2025.

Fosun Pharma’s domestic revenue in 2025 was 28.7 billion yuan, a decrease of 4% year-on-year.

Fosun Pharma’s pharmaceutical revenue in 2025 was 29.83B yuan, up 3.14% from 28.92B yuan last year, accounting for 71.61% of total revenue.

Among them, revenue from innovative drugs in 2025 was 9.89B yuan, an increase of 29.59% year-on-year, accounting for 23.75% of total revenue, an increase of 5.16 percentage points compared to last year, and accounting for 33.16% of pharmaceutical business revenue, an increase of 6.77 percentage points.

Revenue from Pei Jin (Tepotinib injection), Aokangze (Natroparatantaploronositine capsules), Yikeda (Acilanser injection) grew over 30%, while revenue from Hanlikang (Rituximab injection), Hanchuyou (Trastuzumab injection), Hanszhuang (Srluli monoclonal antibody injection) remained steadily growing.

Revenue from medical devices and in vitro diagnostics in 2025 was 4.32B yuan, a slight decrease of 0.05% from 4.32B yuan last year, accounting for 10.37% of total revenue.

Revenue from healthcare services in 2025 was 7.37B yuan, down 3.58% from 7.65B yuan last year, accounting for 17.7%.

Revenue in Mainland China in 2025 was 28.69B yuan, down 3.64% from 29.77 billion yuan last year, accounting for 68.85%.

Overseas revenue in 2025 was 12.98B yuan, up 14.87% from 11.3 billion yuan last year, accounting for 31.15% of total revenue, with a 3.64 percentage point increase in proportion.

CFO Chen Zhanyu Resigns, Huang Zhi Appointed

Recently, Fosun Pharma announced that the board received Chen Zhanyu’s written resignation letter. Due to work arrangements, Chen Zhanyu applied to resign from the position of Chief Financial Officer, effective April 2, 2026.

After resignation, Chen Zhanyu will continue to serve as Senior Vice President of the company. On April 2, 2026, upon nomination by the CEO, the board approved the appointment of Huang Zhi as Senior Vice President and Chief Financial Officer, with a term starting from April 2, 2026, until the end of the current board’s term.

Huang Zhi, holding permanent residency in the United States, joined Fosun Pharma (including Fosun Pharma and its holding subsidiaries/entities) in February 2026. He is currently Senior Vice President, Chief Financial Officer, and Co-President of the Innovative Drugs Business Unit.

Before joining the group, Huang Zhi mainly engaged in finance-related work. From April 2007 to October 2020, he held roles including Business Planning & Analysis Manager for Novartis AG (NYSE: NVS) Oncology Division in the U.S., Head of Finance for Western China, Head of Business Processes and Controls for Greater China, Head of Business Planning & Analysis for Greater China, and Chief Financial Officer for South Korea; from October 2020 to February 2025, he served as Chief Financial Officer for Greater China, Asia-Pacific (excluding China), Global Technology Operations, and Innovation Center at BeiGene, during which he was Global Commercial Finance Head from June 2023 to February 2025; from May 2025 to January 2026, he was Senior Vice President of Corporate Development & Finance at Ascletis Pharma (Stock code: 6855.HK, NASDAQ: AAPG).

Guo Guangchang Controls 36% Equity

As of December 31, 2025, Shanghai Fosun High Technology (Group) Co., Ltd. held 33.32% of shares, HKSCC NOMINEES LIMITED held 20.65%, Hong Kong Securities Clearing Company Limited held 1.94%, and China Securities Finance Corporation held 1.45%.

As of December 31, 2025, Fosun Pharma’s shareholding structure was as follows:

Industrial and Commercial Bank of China – Huatai-PineBridge CSI 300 ETF held 0.79%, Bank of China – China Merchants Securities CSI Biotech Index Class A Securities held 0.7%, China Construction Bank – E Fund CSI 300 Healthcare ETF held 0.64%;

Bank of Shanghai – Yinhua CSI Innovation Drug Industry ETF held 0.58%, China Construction Bank – E Fund CSI 300 ETF (Open-end) held 0.56%, and Wu Liewu held 0.52%.

Fosun controls 72.5% of Fosun International, which in turn controls 100% of Fosun High Technology. Guo Guangchang and Wang Qunbin are the controllers of Fosun International.

Guo Guangchang owns 85.29% of Fosun International, and Wang Qunbin owns the remaining 14.71%. Fosun International owns 100% of Fosun High Technology, which owns 36% of Fosun Pharma, including approximately 33.32% of A-shares directly held by Fosun High Technology and about 2.68% of H-shares held via HKSCC NOMINEES LIMITED.

As of today’s close, Fosun Pharma’s stock price was 26.68 yuan, with a market value of 71.2 billion yuan.